Development and validation of an LC-MS/MS method for the bioanalysis of the major metamizole metabolites in human plasma

Bioanalysis. 2020 Feb;12(3):175-189. doi: 10.4155/bio-2019-0251. Epub 2020 Feb 13.

Abstract

Aim: Metamizole is a frequently used antipyretic and analgesic prodrug, yet its pharmacokinetics has not been thoroughly studied in infants and with coadministered medications. Thus, an LC-MS/MS method was developed to quantify the four major metamizole metabolites in human plasma. Methodology: Pre- and postcolumn infusion was installed to enable robust analyte retention and electrospray ionization following deproteinization of plasma samples. Results: The method was linear (R > 0.996), accurate (93.1-106.0%) and precise (≤12.7%). Mean recovery was more than 91.8% and ion suppression less than 13.1% for all analytes. Pharmacokinetic profiles were reproducible after 4 years at -80°C except for the formylated metabolite (-22.2%). Conclusion: The method fulfilled pertinent criteria of validation guidelines and required only little sample volume. The method therefore qualifies for metamizole analyses in children.

Keywords: LC–MS/MS; bioanalysis; dipyrone; method validation; pediatrics; pharmacokinetics.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / blood*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
  • Chromatography, Liquid / methods*
  • Dipyrone / blood*
  • Dipyrone / pharmacology
  • Humans
  • Plasma / chemistry*
  • Tandem Mass Spectrometry / methods*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Dipyrone